BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 10, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MBI 594AN: Phase I

MBI said its two-part study in 53 patients showed that MBI 594AN was safe, well tolerated, non-irritating and had antimicrobial activity against Propionibacterium acnes. A...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >